Qingdao Vland Biotech INC. engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health...
Vland Biotech released its performance for the first three quarters, with a net profit attributable to the parent company of 61.78 million yuan, a year-on-year increase of 51.24%
Vland Biotech's subsidiary receives registration certificates for two joint applications of new veterinary drugs
Vland Biotech released its semi-annual performance report, with a net profit attributable to the parent company of 26.72 million yuan, a year-on-year decrease of 8.98%
Vland Biotech: The company and its subsidiaries jointly applied for the registration certificate of the new veterinary drug for Mianping ointment, which has been approved
Biological vaccine stocks strengthened, among which, Shen Lian Biomedical rose over 10%, Global Printing 10CM hit the daily limit, Guanhao Biotech and Sinovac Biotech rose over 7%, Saili Medical rose over 5%, Kanglao Weishi, Jinhe Biotechnology, and Vland Biotech rose over 4%, Yongshun Biotech, Dezhan Health, Junzheng Group, and Kanghua Biotech rose over 3%
The animal vaccine sector continues to rise, with Shen Lian Biomedical up over 10%